|
Market Closed -
Euronext Bruxelles
11:55:00 2026-09-03 am EDT
|
After hours 03:07:50 pm | |||
| 220.70 EUR | +0.09% |
|
220.75 | +0.02% |
| Sep. 01 | Global pharma companies that have publicly announced Trump drug pricing agreements | RE |
| Sep. 01 | White House Cuts Deal to Lower Prescription Drug Prices With Nine Companies | MT |
| Market Cap | 42.04B 48.86B 39.45B 36.1B 67.37B 4,619B 67.9B 467B 182B 2,360B 183B 179B 7,602B | P/E 2026 * |
22x | P/E 2027 * | 18.2x |
|---|---|---|---|---|---|
| Enterprise Value | 42.35B 49.22B 39.74B 36.36B 67.86B 4,653B 68.4B 470B 183B 2,378B 185B 181B 7,657B | EV / Sales 2026 * |
4.87x | EV / Sales 2027 * | 4.15x |
| Free-Float |
61.59% | Yield 2026 * |
0.66% | Yield 2027 * | 0.68% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Bruxelles
| UCB | Real-time | |
CBOE
| UCB | Real-time | |
|
London S.E.
| 0NZT | Delayed | |
|
Tradegate
| UNC | Real-time | |
|
Xetra
| UNC | Delayed | |
|
OTC Markets
| UCBJF | Delayed | |
|
Börse Stuttgart
| UNC | Delayed | |
|
Boerse Muenchen
| UNC | Real-time | |
|
Deutsche Boerse AG
| UNC | Delayed | |
|
CBOE
| 0NZT | Real-time | |
|
Wiener Boerse
| UCB | End-of-day quote | |
|
Borsa Italiana
| 4UCB | End-of-day quote |
Last Transcript : UCB
| 1 day | +0.09% | ||
| 1 week | -0.54% | ||
| Current month | +2.51% | ||
| 1 month | -0.32% | ||
| 3 months | -12.39% | ||
| 6 months | -12.73% | ||
| Current year | -7.50% |
| 1 week | 214.3 |  | 223.2 |
| 1 month | 211.6 | | 232.9 |
| Current year | 211.6 | | 289.5 |
| 1 year | 191.2 | | 289.5 |
| 3 years | 65.4 | | 289.5 |
| 5 years | 65.4 | | 289.5 |
| 10 years | 54.84 | | 289.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 67 | 2014-12-31 | |
Sandrine Dufour
DFI | Director of Finance/CFO | 60 | 2020-06-30 |
Alistair Henry
CTO | Chief Tech/Sci/R&D Officer | 59 | 2024-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 2011-12-31 | |
| Director/Board Member | 67 | 2014-12-31 | |
| Director/Board Member | 56 | 2014-04-23 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 1/15/26 | Exercice | Executive/Senior Manager | 3,000 | 0.0015% | ||
| 1/15/26 | Exercice | Executive/Senior Manager | 3,000 | 0.0015% | ||
| 1/15/26 | Buy | Director | 500 | 0.0003% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.09% | -0.54% | +9.26% | +170.07% | 48.73B | |
| -1.26% | +4.17% | +49.23% | +2.24% | 85.08B | |
| -3.34% | +1.86% | +504.70% | +32.98% | 60.21B | |
| +0.95% | +1.77% | -15.77% | -34.78% | 59.71B | |
| -1.60% | -7.63% | -3.65% | +31.05% | 51.1B | |
| +0.72% | +1.32% | +58.47% | -15.72% | 32.9B | |
| -0.38% | +0.66% | +47.86% | +103.19% | 26.11B | |
| +0.79% | -6.56% | -2.56% | +192.31% | 22.6B | |
| +1.10% | -1.67% | +64.17% | +113.16% | 16.42B | |
| -5.19% | -9.15% | -20.45% | +740.91% | 15.3B | |
| Average | -0.80% | -2.42% | +69.12% | +133.54% | 41.82B | |
| Weighted average by Cap. | -0.84% | -1.18% | +90.29% | +71.01% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.7B 10.11B 8.16B 7.47B 13.94B 956B 14.05B 96.58B 37.61B 488B 37.97B 37.14B 1,573B | 9.68B 11.26B 9.09B 8.31B 15.52B 1,064B 15.64B 108B 41.87B 544B 42.27B 41.34B 1,751B |
| Net income | 1.93B 2.25B 1.81B 1.66B 3.1B 212B 3.12B 21.46B 8.36B 109B 8.44B 8.25B 350B | 2.33B 2.71B 2.18B 2B 3.73B 256B 3.76B 25.84B 10.06B 131B 10.16B 9.94B 421B |
| Net Debt | 306M 355M 287M 262M 490M 33.57B 493M 3.39B 1.32B 17.15B 1.33B 1.3B 55.25B | -1.81B -2.1B -1.7B -1.55B -2.9B -199B -2.92B -20.07B -7.82B -102B -7.89B -7.72B -327B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-03 | €220.70 | +0.09% | 205,856 |
| 26-09-02 | €220.50 | +0.92% | 202,075 |
| 26-09-01 | €218.50 | +1.49% | 200,601 |
| 26-08-31 | €215.30 | -0.55% | 312,155 |
| 26-08-28 | €216.50 | -2.43% | 257,379 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- UCB Stock
Select your edition
All financial news and data tailored to specific country editions
